Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13325
UPID:
IFIT5_HUMAN
Alternative names:
Interferon-induced 58 kDa protein; Retinoic acid- and interferon-inducible 58 kDa protein
Alternative UPACC:
Q13325; B2R5X9; B4DDV1; Q5T7I9; Q6IAX3
Background:
Interferon-induced protein with tetratricopeptide repeats 5, also known as the 58 kDa protein, plays a pivotal role in the human innate immune response. It is adept at recognizing a wide range of RNA structures, crucial for antiviral defense. This protein binds to both precursor and processed tRNAs, poly-U-tailed tRNA fragments, and single-stranded RNA with a 5'-triphosphate group, distinguishing viral RNAs from self RNAs. Additionally, it binds AT-rich double-stranded DNA and enhances IKK-NFKB signaling, a key pathway in innate immunity.
Therapeutic significance:
Understanding the role of Interferon-induced protein with tetratricopeptide repeats 5 could open doors to potential therapeutic strategies.